Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.

Raquibul Hannan,Michael Christensen,Aurelie Garant,Hans J. Hammers,Waddah Arafat,Kevin D. Courtney,Isaac Bowman,Suzanne Cole,David J. Sher,Chul Ahn,Robert Timmerman,James Brugarolas

Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.

2021

Raquibul Hannan
Michael Christensen
Aurelie Garant
Hans J. Hammers
Waddah Arafat
Kevin D. Courtney
Isaac Bowman
Suzanne Cole
David J. Sher
Chul Ahn
Robert Timmerman
James Brugarolas

4564Background: Metastatic renal cell carcinoma (mRCC) patients on systemic therapy may experience oligoprogression. SAbR has been demonstrated to be safe and is associated with high local control ...

Keywords:

Radiology
Renal cell carcinoma
Systemic therapy
Medicine
Kidney cancer
Ablative case
SABR volatility model

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations